Tot Biopharm International Co

Tot Biopharm International Co, a Pharmaceutical Preparation Manufacturing company headquartered in China, has not reported its carbon emissions for 2023. In 2022, the company reported total Scope 1 and 2 emissions of about 11,431,000 kg CO2e, comprising approximately 4,516,000 kg CO2e from Scope 1 and 6,915,000 kg CO2e from Scope 2. This represents a decrease from 2021, when Scope 1 and 2 emissions totalled about 15,014,000 kg CO2e, with 4,722,000 kg CO2e from Scope 1 and 10,291,000 kg CO2e from Scope 2. In 2020, their Scope 1 and 2 emissions were approximately 14,769,000 kg CO2e (5,075,000 kg CO2e Scope 1, 9,693,000 kg CO2e Scope 2). In 2019, Tot Biopharm International Co's Scope 1 and 2 emissions were about 11,319,000 kg CO2e, consisting of 3,562,000 kg CO2e from Scope 1 and 7,757,000 kg CO2e from Scope 2. The company has not disclosed any Scope 3 emissions data, and there are no public reduction targets or climate commitments available.